Chronic lymphocytic leukaemia trials in Brazil

In Brazil 13 Also abroad 308

13 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Where
Jaú, São Paulo
Age
18 years and over
People
735 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05947851 · EU 2022-501560-17-00
Phase 2Taking people
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Where
Rio de Janeiro, São Paulo
Age
18 years and over
People
490 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00
Phase 1/2Taking people
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Where
São Paulo, Vitória
Age
18 years and over
People
258 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06697184 · EU 2024-518829-15-00
Phase 3Taking people
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Where
Belo Horizonte, Campinas, Curitiba, Niterói, Porto Alegre, Rio de Janeiro, Salvador, São Paulo, Vitória
Age
18 years and over
People
630 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00
Phase 2Taking people
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
Where
Goiânia, Porto Alegre, São Paulo
Age
18 years to 130 years
People
80 worldwide
Run by
AstraZeneca
See details and how to joinNCT07024706 · EU 2024-518858-17-00
Phase 3Taking people
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Where
Curitiba, Ribeirão Preto, Rio de Janeiro, São Paulo
Age
18 years and over
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136559 · EU 2022-501697-19-01
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Brasília, Curitiba, Porto Alegre, São Paulo
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
Phase 3Taking people
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Where
Belo Horizonte, Brasília, Curitiba, Florianópolis, Joinville, Niterói, Porto Alegre, Rio de Janeiro, Salvador, São Paulo, Vitória
Age
18 years and over
People
250 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06846671 · EU 2024-518893-15-00
Phase 3Taking people
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Where
Araçatuba, Belo Horizonte, Curitiba, Goiânia, Rio de Janeiro, Salvador, São Paulo
Age
18 years and over
People
500 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00
Phase 3Taking people
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Where
Brasília, Porto Alegre, Salvador, São Paulo
Age
18 years and over
People
500 worldwide
Run by
BeOne Medicines
See details and how to joinNCT07277231 · EU 2025-524366-21-00
Phase 3Taking people
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Where
Barretos, Botucatu, Campinas, Cascavel, Curitiba, Passo Fundo, Porto Alegre, Ribeirão Preto, Santo André, São José do Rio Preto, São Paulo
Age
18 years and over
People
737 worldwide
Run by
Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00
Phase 2Taking people
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Where
Porto Alegre, São Paulo
Age
18 years and over
People
75 worldwide
Run by
AbbVie
See details and how to joinNCT04895436 · EU 2023-504599-10-00
Phase 1Taking people
Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
Where
São Paulo
Age
2 years to 70 years
People
30
Run by
Nelson Hamerschlak
See details and how to joinNCT05705570